News

AI in managed care cuts documentation and burnout, but ROI, governance and transparency define success—learn what leaders must track and safeguard.

California health plans Blue Shield Promise and L.A. Care are partnering with the California Black Women’s Collective to help Black women in Los Angeles County gain career skills, mentorship and job opportunities through SheWorks California.

GLP‑1 drugs transform obesity and diabetes care, but soaring employer costs spark new coverage rules, safety concerns, and major pipeline updates.

Zahra Mahmoudjafari shares how The University of Kansas Cancer Center builds sustainable cell and gene therapy programs amid new CMS access rules.

A RAND analysis finds that provisions in the One Big Beautiful Bill Act will reduce Medicaid funding to states by hundreds of billions of dollars over the next decade, driven largely by new work requirements and more frequent eligibility redeterminations that are projected to lower enrollment by millions.

Researchers highlighted the anti-inflammatory benefits of GLP-1 receptor agonists in people with HIV, plus a growing concern over rising STI rates and the cautious promise of doxycycline post-exposure prophylaxis as a partial prevention strategy.

Sharon Faust, of Navitus Health Solutions, said in an interview that employers, health plans and manufacturers must work together to manage costs and access for patients taking GLP-1 medications.

In the first segment of a video interview with MHE, the CEO of Risant Health discusses the role of scale in following value-based practices.

ViiV Healthcare unveiled new data at the Conference on Retroviruses and Opportunistic Infections on next-generation long-acting HIV therapies.

Risant’s CEO, Jaewon Ryu, M.D., J.D., discusses some of the early successes of bringing a set of Kaiser Permanente’s value-based care practices to Risant's health systems—Geisinger Health in Pennsylvania and Cone Health in North Carolina. Consistency and "systemness” are key.

The president slammed the Affordable Care Act and talked up his Great Health Plan and his most favored nation drug pricing policies, highlighting lower prices for fertility drugs.

Cardinal Health 2026 Biosimilars Report shows biosimilars’ savings surge, but predictable reimbursement drives physician adoption amid FDA streamlining.

Catastrophic cases are often a strategic vulnerability for health plans with outsized influence on cost, outcomes and member experience.

An abstract presented at CROI 2026 found that continuous Medicaid coverage during the COVID-19 public health emergency was associated with decreased dependence on AIDS Drug Assistance Programs.

By accommodating the Trump administration's most favored nation drug pricing agenda, the pharmaceutical industry has avoided tariffs and seems likely to do so after the Supreme Court ruling last week.

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

The role of the pharmacist, managed care pharmacist job satisfaction and artificial intelligence were among the topics that Susan A. Cantrell, CEO of the Academy of Managed Care Pharmacy, discussed with Perry Cohen, Pharm.D., in this episode of "Conversations with Perry and Friends."

The deals that drugmakers have struck in response to Trump's most favored nation pricing policies may not be affected, partly because the president has authority to impose tariffs under other statutes.

Early pharmacy leadership helps health systems build safe, sustainable cell and gene therapy programs, aligning contracts, workflows, regulations and payer realities.

Health systems learn why cell and gene therapy success depends on workflows, staffing, and finances—not just science—and how to build them.

Zimbabwe has become one of the first countries in the world to launch a national lenacapavir program, introducing the twice-yearly injectable HIV prevention drug as part of its ongoing efforts to reduce new infections and end AIDS as a public health threat.

In this video interview, Joseph Kleiman, president of Buzz Health, says that patients should always “do their homework” to see if they are paying the lowest possible price for their prescription, whether that’s through TrumpRx or another website.

Researchers say a modest price cut would make semaglutide cost-effective for secondary prevention of cardiovascular disease in the United States.

In this Q&A, Jessica Vazzaz explained what evidence supports sonic sleep aids, who benefits and what payers should demand before covering sleep-disorder apps.

The National Specialty Care Access Coalition aims to standardize care models, modernize reimbursement policies, and pilot programs in cardiology, neurology, and maternal-fetal medicine nationwide.

FDA reviews tirabrutinib for relapsed/refractory primary CNS lymphoma under accelerated approval, with promising phase 2 response rates and a Dec. 2026 decision.